SRC and breast carcinoma: SKI-606, which is an Src inhibitor, decreased the phosphorylation of PyK2 and the migration and invasion of MDA-MB-468 breast cancer cells without affecting proliferation, suggesting that PyK2 induced the migration of breast cancer cells by activating Src [92].